ProKidney refocuses Phase 3 program; discontinues PROACT 2, expects topline results Q3 2027

PROKIDNEY CORP.

Discontinues ex-U.S. PROACT 2 trial; believes PROACT 1 alone may support FDA approval under RMAT designation.
Estimated topline results from PROACT 1 by Q3 2027; expects $150-175M expense reduction.
Cash runway extended to Q1 2027; focused on U.S. market for rilparencel in advanced CKD with type 2 diabetes.
CEO cites positive REGEN-007 interim data as supporting urgency; RMAT designation granted Oct 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.